Syndexa Obtains $15,000,000 Series B Funding

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    767C Concord Avenue Cambridge, MA 02138
  • Company Description
    The company develops drugs targeting novel biological mechanisms for the treatment and prevention of metabolic diseases including obesity, type 2 diabetes and cardiovascular disease.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds purposes were not disclosed.
  • M&A Terms
  • Venture Investor

Trending on Xconomy